Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 16/20 | 0.57 |
| ▸ | MAOA | P21397 | 3/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31254045 | 0.88 | MAOB (0.56) | MAOBMAOAPPARDALDH1A1CYP3A4 | |
| SCHEMBL8417746 | 0.87 | MCL1 (0.53) | PPARDALDH1A1HPGD | |
| SCHEMBL3210641 | 0.87 | MAOB (0.65) | MAOBMAOAPPARDALDH1A1CYP3A4 | |
| SCHEMBL10468411 | 0.86 | CHEK1 (0.50) | MAOBMAOAALDH1A1HPGD | |
| SCHEMBL24474194 | 0.85 | MAOB (0.58) | MAOBMAOAPPARDALDH1A1CYP3A4 | |
| SCHEMBL12428818 | 0.85 | MAOB (0.58) | MAOBMAOAPPARD | |
| SCHEMBL1415014 | 0.85 | MAOB (0.58) | MAOBMAOAPPARD | |
| SCHEMBL27834118 | 0.84 | HMGCR (0.47) | MAOBMAOAALDH1A1HPGD | |
| SCHEMBL28474199 | 0.84 | MAOB (0.57) | MAOBMAOAPPARD | |
| SCHEMBL7404629 | 0.83 | MAOB (0.60) | MAOBMAOAPPARDALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MAOB 2146/4885MAOA 2615/4885PPARD 66/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MAOB 2146/4885MAOA 2615/4885PPARD 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.